

N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma

Status Change – August 14, 2009

NOTICE OF STATUS CHANGE

The study will re-open to the next cohort of 3 patients to the same dose level (dose level -1 in protocol; see section 7) effective today, Friday, August 14, 2009.

Please retain this notice with the protocol.